Lifecore Biomedical (NASDAQ:LFCR) Issues Earnings Results

Lifecore Biomedical (NASDAQ:LFCR) issued its quarterly earnings data on Thursday. The company reported ($0.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.02, Zacks reports. Lifecore Biomedical had a net margin of 5.09% and a negative return on equity of 382.65%.

Lifecore Biomedical Stock Performance

Lifecore Biomedical stock traded down $0.77 during midday trading on Thursday, reaching $6.66. 848,568 shares of the company’s stock were exchanged, compared to its average volume of 214,029. Lifecore Biomedical has a 52 week low of $3.68 and a 52 week high of $8.90. The firm has a market cap of $245.27 million, a price-to-earnings ratio of 83.25 and a beta of 0.99. The stock’s 50-day simple moving average is $6.96 and its 200 day simple moving average is $5.77. The company has a debt-to-equity ratio of 12.90, a quick ratio of 0.80 and a current ratio of 1.83.

Analyst Upgrades and Downgrades

Separately, Craig Hallum increased their target price on Lifecore Biomedical from $8.00 to $10.00 and gave the stock a “buy” rating in a report on Friday, November 22nd.

Lifecore Biomedical Company Profile

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.